Core Insights - The PRIME study, a significant research initiative on preterm birth, has been accepted for publication in a peer-reviewed journal, following its presentation at a medical conference earlier this year [1][2] - Sera Prognostics, Inc. focuses on enhancing maternal and neonatal health through innovative pregnancy biomarker information [1][3] Company Overview - Sera Prognostics is a health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care [3] - The company's PreTRM Test is the only broadly validated, commercially available blood-based biomarker test for early risk prediction of spontaneous preterm birth [4] Product Details - The PreTRM Test analyzes proteins in the blood to predict preterm birth risk in asymptomatic singleton pregnancies, allowing for informed clinical decisions [4] - The test is ordered by medical professionals and provides risk assessments during weeks 18 to 20 of pregnancy [4]

Core Insights - Sera Prognostics Inc. will report its third quarter fiscal year 2025 financial results on November 13, 2025, followed by a conference call to discuss operational highlights and financial results [1][2] Company Overview - Sera Prognostics is dedicated to improving maternal and neonatal health through innovative pregnancy biomarker information, aiming to reduce healthcare delivery costs [3] - The company has a robust pipeline of diagnostic tests focused on early prediction of preterm birth risk and other pregnancy complications [3] - The PreTRM® Test is a key product that provides individualized risk predictions for spontaneous preterm birth, allowing for proactive interventions [5] Industry Context - Preterm birth, defined as any birth before 37 weeks' gestation, is the leading cause of illness and death in newborns, with over 10% of infants born prematurely in the U.S. for the last six years [4] - The annual healthcare costs associated with managing complications from prematurity in the U.S. were estimated at approximately $25 billion in 2016 [4]

Core Viewpoint - Sera Prognostics Inc. has appointed Dr. Tiffany Inglis as Chief Medical Officer to enhance its leadership in women's health diagnostics, particularly focusing on improving maternal and neonatal health through innovative pregnancy biomarker testing [1][2][3]. Company Overview - Sera Prognostics is dedicated to improving the lives of women and babies through precision pregnancy care, aiming to provide early and pivotal pregnancy information to enhance maternal and neonatal health and reduce healthcare delivery costs [4]. Leadership Appointment - Dr. Tiffany Inglis brings extensive clinical leadership experience from Elevance Health and Carelon Health, where she focused on women's and children's health, improving access to quality care while achieving cost savings [2][3]. - Her clinical expertise and experience with major payer networks position her well to lead Sera's clinical operations during a critical phase, including the upcoming publication of the PRIME study and pilot programs with state Medicaid [3][4]. Product Focus - Sera's PreTRM® Test is a blood-based biomarker test that provides early, accurate, and individualized risk predictions for spontaneous preterm birth in asymptomatic singleton pregnancies, allowing for informed clinical decisions [6][7]. - The test measures proteins in the blood that are highly predictive of preterm birth, enabling identification of at-risk women between 18 and 20 weeks of pregnancy [6][7]. Industry Context - Preterm birth, defined as any birth before 37 weeks' gestation, is a leading cause of illness and death in newborns, with over 10% of infants born prematurely in the U.S. for the last six years [5]. - The healthcare costs associated with managing complications from prematurity in the U.S. were estimated at approximately $25 billion in 2016 [5].

Company Overview - Sera Prognostics Inc. is focused on improving maternal and neonatal health through innovative pregnancy biomarker information [3] - The company aims to provide early pregnancy information to enhance the health of mothers and newborns, thereby reducing healthcare delivery costs [3] - Sera Prognostics is headquartered in Salt Lake City, Utah [3] Financial Results Announcement - The company will report its second quarter fiscal year 2025 financial results on August 6, 2025, after market close [1] - A conference call and live webcast will be held at 5:00 p.m. Eastern Time to discuss operational highlights and financial results [1][2] - A press release detailing the financial results will be distributed before the call [1] PreTRM® Test - The PreTRM® Test is a blood-based biomarker test that predicts the risk of spontaneous preterm birth in asymptomatic singleton pregnancies [5] - It measures proteins in the blood that are highly predictive of preterm birth, allowing for early identification of at-risk women [5] - The test enables personalized clinical decisions based on individual risk during weeks 18 to 20 of pregnancy [5] Preterm Birth Context - Preterm birth, defined as birth before 37 weeks' gestation, is the leading cause of illness and death in newborns [4] - Over the last five years, more than 10% of infants in the U.S. have been born prematurely [4] - The annual healthcare costs associated with managing complications from prematurity in the U.S. were estimated at approximately $25 billion in 2016 [4]

Company Overview - Sera Prognostics is a leading health diagnostics company focused on improving the lives of women and babies through precision pregnancy care [3] - The company's mission is to provide early, pivotal pregnancy information to enhance maternal and newborn health, ultimately reducing healthcare delivery costs [3] - Sera has a robust pipeline of innovative diagnostic tests aimed at early prediction of preterm birth risk and other pregnancy complications [3] Leadership Appointment - Mr. Lee Anderson has been appointed to a leadership role at Sera Prognostics, bringing extensive experience in the biotechnology and diagnostics sector [1] - Anderson previously held significant positions at Genomic Health and Exact Sciences, where he led US Oncology Sales and Global Customer Service, achieving nine consecutive years of revenue growth [1][2] - His role at Biofidelity Inc. as Chief Commercial Officer further enhanced his commercial strategy expertise and market presence [2] PreTRM® Test - The PreTRM® Test is the only broadly validated, commercially available blood-based biomarker test that provides early, accurate, and individualized risk predictions for spontaneous preterm birth in asymptomatic singleton pregnancies [5] - This test analyzes proteins in the blood that are highly predictive of preterm birth, allowing physicians to identify at-risk women between weeks 18 and 20 of pregnancy [5] - The PreTRM® Test enables more informed and personalized clinical decisions based on individual risk assessments [5] Preterm Birth Context - Preterm birth, defined as any birth before 37 weeks' gestation, is the leading cause of illness and death in newborns [4] - Over the last six years, more than one in ten infants in the United States has been born prematurely, leading to significant long-term medical complications [4] - The estimated annual healthcare costs for managing complications related to prematurity in the U.S. were approximately $25 billion in 2016 [4]

Company Overview - Sera Prognostics Inc. is focused on improving maternal and neonatal health through innovative pregnancy biomarker information [3] - The company aims to provide early pregnancy information to enhance the health of mothers and newborns, thereby reducing healthcare delivery costs [3] - Sera Prognostics is headquartered in Salt Lake City, Utah [3] Financial Results Announcement - The company will report its first quarter fiscal year 2025 financial results on May 7, 2025, after market close [1] - A conference call and live webcast will be held at 5:00 p.m. Eastern Time to discuss operational highlights and financial results [1][2] - A press release with financial results will be distributed before the call [1] PreTRM® Test - The PreTRM® Test is a blood-based biomarker test that predicts the risk of spontaneous preterm birth in asymptomatic singleton pregnancies [5] - It measures proteins in the blood that are highly predictive of preterm birth, allowing for early identification of at-risk women [5] - The test enables personalized clinical decisions based on individual risk during weeks 18 to 20 of pregnancy [5] Preterm Birth Context - Preterm birth is defined as any birth before 37 weeks' gestation and is a leading cause of illness and death in newborns [4] - Over the last five years, more than 10% of infants in the U.S. have been born prematurely [4] - The annual healthcare costs for managing complications of prematurity in the U.S. were estimated at approximately $25 billion in 2016 [4]